Blocking of Histamine Release and IgE Binding to FcepsilonRI on Human Basophils by Antibodies Produced in Camels
Allergy, Asthma & Immunology Research
; : 583-589, 2015.
Article
in En
| WPRIM
| ID: wpr-89920
Responsible library:
WPRO
ABSTRACT
PURPOSE: The production of camel heavy-chain antihuman IgE (huIgE) that has the potential to block IgE-FcepsilonRI interaction and histamine release by basophils. METHODS: Camels were immunized with a synthetic loop peptide (SLP) designed in a multiple antigen peptide system (MAPS) forming SLP-MAPS immunogen. Camel polyclonal antibodies (PCAs) were produced, purified, characterized using Protein A & G, ELISA, and SDS-PAGE, and tested for their potency to block passive sensitization and histamine release of human basophils using flow cytometry (FCM) and ELISA, respectively. RESULTS: FCM data indicated that camel conventional (IgG1) and heavy chain antibodies (HCAbs; IgG2, and IgG3) had blocking activities of 43.9%, 72%, and 96.6%, respectively. Moreover, both IgG2 and IgG3 achieved remarkable inhibition rates of 93.98% and 97.05% in histamine release, respectively, whereas the IgG1inhibiting activity was 60.05%. CONCLUSIONS: Camel PCAs produced against SLP-MAPS were capable of blocking the IgE-receptor interaction and the release of histamine by basophils with superiority to HCAbs. These findings may pave the way toward the possible use of camel anti-huIgE HCAbs as blocking antibodies in the treatment of IgE-mediated allergy and asthma.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Asthma
/
Staphylococcal Protein A
/
Basophils
/
Immunoglobulin E
/
Immunoglobulin G
/
Camelus
/
Enzyme-Linked Immunosorbent Assay
/
Passive Cutaneous Anaphylaxis
/
Histamine
/
Antibodies, Blocking
Limits:
Humans
Language:
En
Journal:
Allergy, Asthma & Immunology Research
Year:
2015
Type:
Article